Identification of potential blood biomarkers for early diagnosis of Alzheimer's disease through RNA sequencing analysis.
Alzheimer’s disease
Biomarkers for early diagnosis
RNA sequencing
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
16 07 2020
16 07 2020
Historique:
received:
16
02
2020
accepted:
08
07
2020
entrez:
18
7
2020
pubmed:
18
7
2020
medline:
25
6
2021
Statut:
epublish
Résumé
With demographic shifts toward older populations, the number of people with dementia is steadily increasing. Alzheimer's disease (AD) is the most common cause of dementia, and no curative treatment is available. The current best strategy is to delay disease progression and to practice early intervention to reduce the number of patients that ultimately develop AD. Therefore, promising novel biomarkers for early diagnosis are urgently required. To identify blood-based biomarkers for early diagnosis of AD, we performed RNA sequencing (RNA-seq) analysis of 610 blood samples, representing 271 patients with AD, 91 cognitively normal (CN) adults, and 248 subjects with mild cognitive impairment (MCI). We first estimated cell-type proportions among AD, MCI, and CN samples from the bulk RNA-seq data using CIBERSORT and then examined the differentially expressed genes (DEGs) between AD and CN samples. To gain further insight into the biological functions of the DEGs, we performed gene set enrichment analysis (GSEA) and network-based meta-analysis. In the cell-type distribution analysis, we found a significant association between the proportion of neutrophils and AD prognosis at a false discovery rate (FDR) < 0.05. Furthermore, a similar trend emerged in the results of routine blood tests from a large number of samples (n = 3,099: AD, 1,605; MCI, 994; CN, 500). In addition, GSEA and network-based meta-analysis based on DEGs between AD and CN samples revealed functional modules and important hub genes associated with the pathogenesis of AD. The risk prediction model constructed by using the proportion of neutrophils and the most important hub genes (EEF2 and RPL7) achieved a high AUC of 0.878 in a validation cohort; when further applied to a prospective cohort, the model achieved a high accuracy of 0.727. Our model was demonstrated to be effective in prospective AD risk prediction. These findings indicate the discovery of potential biomarkers for early diagnosis of AD, and their further improvement may lead to future practical clinical use.
Sections du résumé
BACKGROUND
With demographic shifts toward older populations, the number of people with dementia is steadily increasing. Alzheimer's disease (AD) is the most common cause of dementia, and no curative treatment is available. The current best strategy is to delay disease progression and to practice early intervention to reduce the number of patients that ultimately develop AD. Therefore, promising novel biomarkers for early diagnosis are urgently required.
METHODS
To identify blood-based biomarkers for early diagnosis of AD, we performed RNA sequencing (RNA-seq) analysis of 610 blood samples, representing 271 patients with AD, 91 cognitively normal (CN) adults, and 248 subjects with mild cognitive impairment (MCI). We first estimated cell-type proportions among AD, MCI, and CN samples from the bulk RNA-seq data using CIBERSORT and then examined the differentially expressed genes (DEGs) between AD and CN samples. To gain further insight into the biological functions of the DEGs, we performed gene set enrichment analysis (GSEA) and network-based meta-analysis.
RESULTS
In the cell-type distribution analysis, we found a significant association between the proportion of neutrophils and AD prognosis at a false discovery rate (FDR) < 0.05. Furthermore, a similar trend emerged in the results of routine blood tests from a large number of samples (n = 3,099: AD, 1,605; MCI, 994; CN, 500). In addition, GSEA and network-based meta-analysis based on DEGs between AD and CN samples revealed functional modules and important hub genes associated with the pathogenesis of AD. The risk prediction model constructed by using the proportion of neutrophils and the most important hub genes (EEF2 and RPL7) achieved a high AUC of 0.878 in a validation cohort; when further applied to a prospective cohort, the model achieved a high accuracy of 0.727.
CONCLUSIONS
Our model was demonstrated to be effective in prospective AD risk prediction. These findings indicate the discovery of potential biomarkers for early diagnosis of AD, and their further improvement may lead to future practical clinical use.
Identifiants
pubmed: 32677993
doi: 10.1186/s13195-020-00654-x
pii: 10.1186/s13195-020-00654-x
pmc: PMC7367375
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
87Références
Nature. 2008 Mar 27;452(7186):423-8
pubmed: 18344981
BMJ. 2015 Jun 16;350:h3029
pubmed: 26079686
Am J Physiol Cell Physiol. 2017 Jul 1;313(1):C3-C10
pubmed: 28424166
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Methods Mol Biol. 2018;1711:243-259
pubmed: 29344893
Nat Genet. 2019 Mar;51(3):414-430
pubmed: 30820047
Stat Methods Med Res. 2013 Oct;22(5):519-36
pubmed: 22127579
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Aging Ment Health. 2019 Jul;23(7):840-850
pubmed: 30351202
Med Chem. 2016;12(3):226-37
pubmed: 26527156
J Clin Neurol. 2009 Dec;5(4):153-66
pubmed: 20076796
Arch Neurol. 2011 Sep;68(9):1137-44
pubmed: 21555603
Nucleic Acids Res. 2019 Jan 8;47(D1):D590-D595
pubmed: 30321428
Biol Proced Online. 2001 Nov 16;3:19-25
pubmed: 12734582
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
JAMA Neurol. 2019 Jul 1;76(7):791-799
pubmed: 31009028
Alzheimers Dement. 2011 May;7(3):270-9
pubmed: 21514249
Science. 2009 Oct 16;326(5951):386-9
pubmed: 19833956
Dis Markers. 2016;2016:4250480
pubmed: 27418712
J Clin Invest. 2019 Feb 1;129(2):820-833
pubmed: 30667373
Mol Neurodegener. 2018 Dec 17;13(1):65
pubmed: 30558641
Nat Genet. 2000 May;25(1):25-9
pubmed: 10802651
Curr Protoc Bioinformatics. 2014 Sep 08;47:8.13.1-24
pubmed: 25199793
Front Neurosci. 2019 Mar 28;13:235
pubmed: 30983949
J Alzheimers Dis. 2016 Oct 4;54(3):1147-1155
pubmed: 27567861
N Engl J Med. 2013 Aug 8;369(6):540-8
pubmed: 23924004
Mol Clin Oncol. 2018 Dec;9(6):597-606
pubmed: 30546887
Neuropsychiatr Dis Treat. 2018 Jul 20;14:1877-1882
pubmed: 30050302
Commun Biol. 2019 Feb 25;2:77
pubmed: 30820472
Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361
pubmed: 27899662
BMC Bioinformatics. 2011 Aug 04;12:323
pubmed: 21816040
Genome Biol. 2010;11(10):R106
pubmed: 20979621
J Proteome Res. 2019 Jul 5;18(7):2940-2953
pubmed: 31136180
J Alzheimers Dis. 2013;34(1):239-62
pubmed: 23229080
Mol Med Rep. 2015 Jul;12(1):1125-30
pubmed: 25776533
J Prim Care Community Health. 2011 Oct 1;2(4):229-33
pubmed: 23804840
J Epidemiol Community Health. 2017 Feb;71(2):115-120
pubmed: 27440936
PLoS One. 2010 Oct 11;5(10):e13250
pubmed: 20948999
Nat Med. 2020 Mar;26(3):379-386
pubmed: 32123385
Ann Neurol. 2018 Feb;83(2):387-405
pubmed: 29369398
Nucleic Acids Res. 2011 Jan;39(Database issue):D561-8
pubmed: 21045058
Nucleic Acids Res. 2009 Jan;37(1):1-13
pubmed: 19033363
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
J Am Geriatr Soc. 2011 Sep;59(9):1705-10
pubmed: 21883100
Cell Rep. 2016 May 17;15(7):1455-1466
pubmed: 27160897
J Neurosci. 2012 Jun 13;32(24):8270-83
pubmed: 22699908
Cell Signal. 2011 Feb;23(2):324-34
pubmed: 20813183
Nat Genet. 2019 Mar;51(3):404-413
pubmed: 30617256
Proc Natl Acad Sci U S A. 2015 Feb 17;112(7):2257-62
pubmed: 25646437
Alzheimers Dement. 2019 Oct;15(10):1333-1347
pubmed: 31473137
Nature. 2003 Mar 20;422(6929):297-302
pubmed: 12646919
Bioinformatics. 2015 Sep 1;31(17):2912-4
pubmed: 25964631
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
Arch Neurol. 2010 Aug;67(8):949-56
pubmed: 20697045
PLoS Genet. 2005 Dec;1(6):e78
pubmed: 16362079
Gene. 2014 Jul 25;545(2):185-93
pubmed: 24838203